Breast Cancer
Conference Coverage
PD-L1 expression best predicts response to atezolizumab + nab-paclitaxel for mTNBC
SAN ANTONIO – IMpassion130 analyses show that PD-L1 expression on tumor-infiltrating immune cells is the best...
Conference Coverage
No boost in OS with addition of capecitabine for early TNBC
SAN ANTONIO – Adding adjuvant capecitabine to surgery and standard chemotherapy did not improve disease-free or overall survival in women with...
Expert Commentary
More than one-third of tumors found on breast cancer screening represent overdiagnosis
These findings are according to a new study, but the results are similar to those previously reportedThe purpose of screening mammography is to...
From the Editor
Women’s Preventive Services Initiative Guidelines provide consensus for practicing ObGyns
In a remarkable demonstration of collaboration and unity, 21 independent major health organizations have reached agreement on 9 high-priority...
Commentary
Intervention may improve genetic testing for HBOC
Improving genetic screening and testing completion rates requires a coordinated effort.
Medicolegal Issues
Patient with a breast mass: Why did she pursue litigation?
A delay in diagnosing breast cancer is a leading cause of malpractice claims against gynecologists CASE After routine mammography results, DCIS...
From the Journals
ICYMI: Hereditary cancer screening feasible in community gynecologic practices
Surgical Techniques
Modern breast surgery: What you should know
Advances in imaging, surgery, and targeted therapy offer patients with breast cancer good outcomes and improved quality of life. Your...
Conference Coverage
HDAC/aromatase inhibitor combo shows promise for HR+/HER2- advanced breast cancer
MUNICH – Chidamide + exemestane combination therapy increased PFS by about 4 months, compared with exemestane...
Expert Commentary
Does extending aromatase-inhibitor use from 5 to 10 years benefit menopausal women with hormone-positive breast cancer?
In terms of improving the 5-year disease-free survival (DFS) rate, yes, according to results of a randomized study that compared extended...
Conference Coverage
PALOMA-3: Overall survival better for endocrine-sensitive patients only
MUNICH –